Skip to main content

Table 6 Causes of deviation from guidelines for every drug and diagnosis in %

From: Patient and physician related factors of adherence to evidence based guidelines in diabetes mellitus type 2, cardiovascular disease and prevention: a cross sectional study

Causes of deviation from guidelines from patient’s view

n

69

8

15

8

4

15

53

12

21

Reason (in %)

Anti-HT

Metformin

HF: βB

HF: RAAS-I

HF: AldoA

AF: OAK

CVD: statin

CVD: antipltlt

MCI: βB

I don’t know

91.3

50.0

60.0

62.5

75.0

66.7

30.2

50.0

76.2

I don’t need it

2.9

25.0

26.7

37.5

25.0

 

45.3

25.0

9.5

I don’t want it

 

12.5

   

13.3

7.5

  

Adverse drug event

4.3

 

13.3

  

6.7

7.5

 

4.8

Falsely discontinued

1.4

12.5

   

13.3

9.4

25.0

9.5

Causes of deviation from guidelines from physician’s view

n

69

8

15

8

4

15

53

12

21

Reason (in %)

Anti-HT

Metformin

HF: βB

HF: RAAS-I

HF: AldoA

AF: OAK

CVD: statin

CVD: PAI

MCI: βB

Falsely not indicated GP

78.3

37.5

80.0

62.5

50.0

33.3

56.6

33.3

52.4

Falsely not indicated s/h

8.7

12.5

6.7

25.0

25.0

6.7

7.5

8.3

23.8

Noncompliance

2.9

25.0

   

20.0

17.0

25.0

9.5

Adverse drug event

8.7

25.0

6.7

12.5

25.0

6.7

11.3

25.0

4.8

Falsely discontinued

1.4

 

6.7

  

6.7

3.8

  

Contraindication

     

26.7

 

8.3

9.5

Avoidance of polypharmacy

      

3.8

  
  1. Summation does not add up to 100% due to rounding error.
  2. Anti-HT: antihypertensive medication (RAAS-inhibitor or thiazide or calcium channel blocker or β-blocker).
  3. Metformin: metformin in diabetes mellitus type 2 patients.
  4. HF = heart failure.
  5. βB: beta adrenoceptor blocker.
  6. RAAS-I: inhibitor of the renin-angiotensin-aldosterone system.
  7. AldoA: aldosterone antagonist.
  8. AF = atrial fibrillation.
  9. OAK: oral anticoagulation.
  10. CVD = cardiovascular disease.
  11. PAI: platelet aggregation inhibitor (acetylsalicylic acid or clopidogrel/prasugrel).
  12. MCI = myocardial infarction.